These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39051006)

  • 1. Susceptibility evaluation and PK/PD integration of tulathromycin against
    Wang H; Zhang L
    Front Vet Sci; 2024; 11():1407907. PubMed ID: 39051006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation the kill rate and mutant selection window of danofloxacin against Actinobacillus pleuropneumoniae in a peristaltic pump model.
    Wang H; Liao C; Ding K; Zhang L; Wang L
    BMC Vet Res; 2024 Jun; 20(1):241. PubMed ID: 38831324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the mutant selection window of danofloxacin against
    Zhang L; Wang H; Bai Y; Wang L; Bai Y; Hu J
    Front Vet Sci; 2023; 10():1107608. PubMed ID: 36793382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic/Pharmacodynamic Relationships of Tulathromycin Against
    Yao L; Yang L; Ling Y; Wei Y; Shen X; Ding H
    Front Vet Sci; 2022; 9():822432. PubMed ID: 35419449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal regimens based on PK/PD cutoff evaluation of ceftiofur against Actinobacillus pleuropneumoniae in swine.
    Sun D; Mi K; Hao H; Xie S; Chen D; Huang L
    BMC Vet Res; 2020 Sep; 16(1):366. PubMed ID: 32993661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic assessment of cefquinome against Actinobacillus Pleuropneumoniae in a piglet tissue cage infection model.
    Zhang L; Wu X; Huang Z; Zhang N; Wu Y; Cai Q; Shen X; Ding H
    Vet Microbiol; 2018 Jun; 219():100-106. PubMed ID: 29778180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/Pharmacodynamic Integration to Evaluate the Changes in Susceptibility of
    Zhang L; Kang Z; Yao L; Gu X; Huang Z; Cai Q; Shen X; Ding H
    Front Microbiol; 2018; 9():2445. PubMed ID: 30369920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of tulathromycin against Haemophilus parasuis in an experimental neutropenic guinea pig model.
    Zhao Y; Guo LL; Fang B; Liu B
    PLoS One; 2018; 13(12):e0209177. PubMed ID: 30596709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine Thigh Microdialysis to Evaluate the Pharmacokinetic/Pharmacodynamic Integration of Cefquinome Against
    Zhang L; Zhou Z; Gu X; Huang S; Shen X; Ding H
    Front Vet Sci; 2020; 7():448. PubMed ID: 32851028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/Pharmacodynamic Modeling of Tulathromycin against
    Zhou Q; Zhang G; Wang Q; Liu W; Huang Y; Yu P; Li Y; Ding H; Fang B
    Front Pharmacol; 2017; 8():392. PubMed ID: 28701951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kill Rate and Evaluation of
    Zhang L; Xie H; Wang H; Ding H; Zhang G; Hu J
    Front Vet Sci; 2021; 8():751957. PubMed ID: 34966804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence and Mechanism of Resistance of Tulathromycin Against
    Xia X; Yang L; Ling Y; Yu J; Ding H
    Front Vet Sci; 2022; 9():801800. PubMed ID: 35224081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
    Blondeau JM; Fitch SD
    PLoS One; 2019; 14(1):e0210154. PubMed ID: 30629633
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Guo LL; Gao RY; Wang LH; Lin SJ; Fang BH; Zhao YD
    Front Vet Sci; 2021; 8():715887. PubMed ID: 34869712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung microdialysis and
    Chen Y; Li M; Su D; Xiong S; Feng Y; Deng Q; Ding H
    Front Vet Sci; 2024; 11():1390336. PubMed ID: 38596468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of Actinobacillus pleuropneumoniae infection on tulathromycin pharmacokinetics and lung tissue disposition in pigs.
    Gajda A; Bladek T; Jablonski A; Posyniak A
    J Vet Pharmacol Ther; 2016 Apr; 39(2):176-82. PubMed ID: 26270490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic Evaluation and PK/PD-Based Dose Prediction of Tulathromycin: A Potential New Indication for
    Zhou YF; Peng HM; Bu MX; Liu YH; Sun J; Liao XP
    Front Pharmacol; 2017; 8():684. PubMed ID: 29033841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing tylosin dosage for co-infection of
    Lee EB; Abbas MA; Park J; Tassew DD; Park SC
    Front Pharmacol; 2023; 14():1258403. PubMed ID: 37808183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model.
    Zhang B; Gu X; Li Y; Li X; Gu M; Zhang N; Shen X; Ding H
    BMC Vet Res; 2014 Dec; 10():297. PubMed ID: 25511985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
    Dorey L; Pelligand L; Cheng Z; Lees P
    PLoS One; 2017; 12(5):e0177568. PubMed ID: 28552968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.